Inactive Instrument

Press Releases Ra Pharmaceuticals, Inc.

Equities

US74933V1089

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

RA PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	20-04-02	AQ
RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	20-03-31	AQ
RA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	20-03-16	AQ
Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day and Joins Global Movement to Raise Awareness for Rare Diseases	20-03-02	AQ
RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	20-02-28	AQ
Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases	20-02-28	BU
Ra Pharmaceuticals : Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update	20-02-27	BU
RA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	20-02-27	AQ
Ra Pharmaceuticals : Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology	20-02-18	BU
Ra Pharmaceuticals : Announces Clearance of IND Application for the HEALEY ALS Platform Trial	20-01-22	BU
RA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	19-12-18	AQ
Ra Pharmaceuticals : Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM	19-12-04	BU
RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	19-11-25	AQ
Ra Pharmaceuticals : Reports Third Quarter 2019 Financial Results and Provides Corporate Update	19-11-07	BU
RA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ra Pharmaceuticals, Inc. - RARX	19-10-14	BU
WeissLaw LLP Investigates Ra Pharmaceuticals, Inc.	19-10-10	PR
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases	19-10-10	BU
Ra Pharmaceuticals : Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG	19-10-02	BU
Ra Pharmaceuticals : Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General	19-09-18	BU
Ra Pharmaceuticals : Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis	19-09-04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ra Pharmaceuticals, Inc.

Equities

US74933V1089

Press Releases

Filters